# Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry <br> Journal home page: www.ajpamc.com 



## SYNTHESIS, SCREENING AND QSAR ANALYSIS OF CHALCONE DERIVATIVES AS POTENTIAL ANTI BACTERIAL AGENTS

Vudumula Kotireddy*1 and K. Venkata Ramana ${ }^{1}$<br>${ }^{1 *}$ Department of Pharmaceutical Chemistry, A. S. N Pharmacy College, Burripalem Road, Tenali, Andhra Pradesh, India.


#### Abstract

Chalcones are prepared by claisen Schmidt condensation method they are used to prepare various heterocyclic compounds. Most of them are widely used in pharmaceuticals. Keeping this in mind new chalcones are synthesised and the structures were confirmed by IR, NMR and elemental analysis. Synthesised compounds were screened for their antibacterial activity the molecules were screened for their structural activity relationships by atom based 3D QSAR studies.


## KEYWORDS

Chalcones, QSAR and Antibacterial activity.

## Author for Correspondence:

Vudumula Kotireddy,
Department of Pharmaceutical Chemistry,
A.S.N Pharmacy College,

Tenali, Andhra Pradesh, India.

Email: vkotireddy9@ gmail.com

Available online: www.uptodateresearchpublication.com

## INTRODUCTION

Chalcones, a group of compounds prepared by claisen Schmidt condensation they contain two aromatic rings joined by a keto-vinyl group, constitute an important class of naturally occurring flavonoids exhibiting a wide spectrum of biological activities. $\alpha, \beta$-unsaturated keto vinyl functional group is responsible for the biological activity.
General procedure for the synthesis of chalcones
A mixture of 4-chloroacetophenone ( 0.0001 mole ) and the appropriate aryl aldehyde ( 0.0001 mole ) was stirred in ethanol ( 3.5 mL ) and to it aqueous solution January - March
of $\mathrm{KOH}(75 \%, 3.5 \mathrm{~mL})$ was added. The mixture was kept for 24 hours and it was acidified with dil. Hydrochloric acid and water, precipitate was obtained and the product was washed with cold water. Characterization of chalcones were given in Table No.1-3.

## BIOLOGICAL EVALUATION Antibacterial activity

The antibacterial activity of the synthesized chalcones was done by determining the MIC, which is defined as the lowest concentration of the compound that completely inhibited the growth of each strain after overnight incubation. MIC was determined using serial tube dilution technique. In this technique the tubes of broth medium containing graded doses of compounds were inoculated with the test organisms. After suitable incubation, growth occurred in those tubes where the concentration of the compound was below the inhibitory level and the culture become turbid. No growth was noticed above the inhibitory level and the tubes remained clear. Results were given in Table No.5.

## RESULTS AND DISCUSSION

From the above results it is clear that all the chalcones synthesized, showed antibacterial activity with different MIC values against the tested organisms, but not comparable with that of the standard. Out of 25 compounds tested, compound $\mathrm{B}_{5}$ which is having difluorophenyl moiety was found to be the most potent against B.subtilis, E.coli and P.vulgaris having a MIC value of $33 \mu \mathrm{~g} / \mathrm{mL}$ in each case. The chalcones, $\mathrm{B}_{6}$ having a dichlorophenyl substitution, $\mathrm{B}_{7}$ having 2-chloro-5nitrophenyl substitution and $\mathrm{B}_{15}$ having bromofuran substitution were also found to be equipotent with a MIC value of $33 \mu \mathrm{~g} / \mathrm{mL}$ against E.coli, B.subtilis and E.coli respectively.

Atom based 3D-QSAR model for antibacterial activity of chalcones against B.subtilis
In atom based 3D-QSAR analysis of chalcones, the Correlation Coefficient $\left(\mathrm{R}^{2}\right)=0.7922$, Cross validation Coefficient $\left(\mathrm{Q}^{2}\right)=0.4647$ and Standard Deviation (S.D) $=0.1406$ were established. From the it was found that the aromatic ring substitution with hydrogen bond donor or electron withdrawing group or hydrophobic group and a conjugated carbonyl system essential for increasing the antibacterial activity, as such regions showed blue cubes characteristic of positive effect on the antibacterial activity. Results of the statistical analysis are shown in the following tables and figures.
Atom based 3D-QSAR model for antibacterial activity of chalcones against S.aureus
In atom based 3D-QSAR analysis of chalcones, the Correlation Coefficient $\left(\mathrm{R}^{2}\right)=0.9031$, Cross validation Coefficient $\left(\mathrm{Q}^{2}\right)=0.4858$ and Standard Deviation (S.D) $=0.0765$ (Table No.3, 5) were established. From the results shown in figures. It was found that the aromatic ring substitution with hydrogen bond donor or electron withdrawing group or hydrophobic group and a conjugated carbonyl system essential for increasing the antibacterial activity, as such regions showed blue cubes characteristic of positive effect on the antibacterial activity. Results of the statistical analysis are shown in the following tables and figures.

Vudumula Kotireddy and Venkata Ramana K. / Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry. 5(1), 2017, 1-12.
Table No.1: Physical characterization data of chalcones ( $\mathrm{B}_{1}-\mathrm{B}_{25}$ )


Available online: www.uptodateresearchpublication.com January - March

Vudumula Kotireddy and Venkata Ramana K. / Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry. 5(1), 2017, 1-12.

| 13 | B13 |  | $\mathrm{C}_{16} \mathrm{H}_{10} \mathrm{CLO}_{3}$ | 286 | 148-151 | 76 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 14 | B14 |  | $\mathrm{C}_{19} \mathrm{H}_{14} \mathrm{CLN}_{2} \mathrm{O}$ | 322 | 112-115 | 70 |
| 15 | B15 |  | $\mathrm{C}_{13} \mathrm{H}_{7} \mathrm{CLBrO}_{2}$ | 311 | 126-129 | 76 |
| 16 | $\mathbf{B}_{16}$ | $\mathrm{NCH}_{3}$ | $\mathrm{C}_{17} \mathrm{H}_{15} \mathrm{CLNO}$ | 285 | 152-155 | 84 |
| 17 | B17 |  | $\mathrm{C}_{16} \mathrm{H}_{12} \mathrm{CLO}_{3}$ | 288 | 99-102 | 85 |
| 18 | B18 |  | $\mathrm{C}_{14} \mathrm{H}_{9} \mathrm{CLNO}$ | 243 | 91-94 | 83 |
| 19 | B19 |  | $\mathrm{C}_{14} \mathrm{H}_{9} \mathrm{CLNO}$ | 243 | 78-81 | 82 |
| 20 | $\mathbf{B}_{20}$ |  | $\mathrm{C}_{14} \mathrm{H}_{9} \mathrm{CLNO}$ | 243 | 96-99 | 88 |
| 21 | $\mathbf{B}_{21}$ |  | $\mathrm{C}_{13} \mathrm{H}_{9} \mathrm{CLNO}$ | 231 | 101-104 | 66 |
| 22 | $\mathbf{B}_{22}$ |  | $\mathrm{C}_{13} \mathrm{H}_{8} \mathrm{CLOS}$ | 248 | 106-109 | 77 |
| 23 | $\mathbf{B}_{23}$ |  | $\mathrm{C}_{23} \mathrm{H}_{14} \mathrm{CLO}$ | 342 | 108-111 | 85 |
| 24 | $\mathbf{B}_{24}$ |  | $\mathrm{C}_{15} \mathrm{H}_{10} \mathrm{CLO}_{2}$ | 258 | 91-94 | 84 |
| 25 | $\mathrm{B}_{25}$ |  | $\mathrm{C}_{15} \mathrm{H}_{10} \mathrm{CLO}$ | 242 | 66-69 | 82 |

Available online: www.uptodateresearchpublication.com January - March

Vudumula Kotireddy and Venkata Ramana K. / Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry. 5(1), 2017, 1-12.
Table No.2: IR (KBR disc) spectral data of chalcones

| S.No | Compound | Position of absoption band ( $\mathrm{cm}^{-1}$ ) |
| :---: | :---: | :---: |
| 1 | $\mathrm{B}_{1}$ | 1655 ( C=O), 1602 ( C=C of Ar), 1505( $\mathrm{CH}=\mathrm{CH}$ ), 925 (C-F) |
| 2 | $\mathrm{B}_{2}$ | 1664 ( C=O), 1580 ( C=C of Ar), 1524 (CH=CH), 928 (C-F) |
| 3 | $\mathrm{B}_{3}$ | 1653 (C=O), 1585 ( C=C of Ar), 1505 ( CH=CH), 835 (C-Cl), 923 (C-F) |
| 4 | B4 | 1652 ( C=O), 1583 ( C=C of Ar), 1502 (CH=CH), 833 (C-Cl), 923 (C-F) |
| 5 | B5 | 1655 ( C=O), 1581 ( C=C of Ar), 1510 (CH=CH), 925 (C-F), 926 (C-F) |
| 6 | $\mathrm{B}_{6}$ | 1663 ( C=O), 1578 ( C=C of Ar), 1506 (CH=CH), 833 (C-Cl), 921 (C-F) |
| 7 | $\mathrm{B}_{7}$ | 1658 ( $\mathrm{C}=\mathrm{O}$ ), 1603 ( $\mathrm{C}=\mathrm{C}$ of Ar ), $1515(\mathrm{CH}=\mathrm{CH}), 824(\mathrm{C}-\mathrm{Cl}), 1525$ (N=O, asymmetric), 1348 ( $\mathrm{N}=\mathrm{O}$, symmetric), 929 (C-F) |
| 8 | $\mathrm{B}_{8}$ | $1655(\mathrm{C}=\mathrm{O}), 1605(\mathrm{C}=\mathrm{C}$ of Ar$), 1508(\mathrm{CH}=\mathrm{CH}), 1533(\mathrm{~N}=\mathrm{O}$, asymmetric), $1345(\mathrm{~N}=\mathrm{O}$, symmetric), 925 (C-F) |
| 9 | B9 | symmetric), 923 (C-F) |
| 10 | $\mathrm{B}_{10}$ | 3520 ( O-H), 1648 (C=O), 1612 (C=C of Ar), 1505 (CH=CH), 923 (C-F) |
| 11 | $\mathrm{B}_{11}$ | $1655(\mathrm{C}=\mathrm{O}), 1605(\mathrm{C}=\mathrm{C}$ of Ar$), 1500(\mathrm{CH}=\mathrm{CH}), 1545(\mathrm{~N}=\mathrm{O}$, asymmetric $), 1343(\mathrm{~N}=\mathrm{O}$, |
| 12 | $\mathrm{B}_{12}$ | 1652 (C=O), 1585 (C=C of Ar), 1462 (CH=CH), 1127 (-O-CH3), 927 (C-F) |
| 13 | $\mathrm{B}_{13}$ | 1643 (C=O), 1574 ( $\mathrm{C}=\mathrm{C}$ of Ar), 1500 ( $\mathrm{CH}=\mathrm{CH}$ ), 1240 ( $\left.\mathrm{O}-\mathrm{CH}_{2}-\mathrm{O}\right), 929$ (C-F) |
| 14 | $\mathrm{B}_{14}$ | 1663 (C=O), 1610 (C=N), 1588 (C=C of Ar), 1510 (CH=CH), 1391 (C-N), 921 (C-F) |
| 15 | $\mathrm{B}_{15}$ | 1652 (C=O), 1585 (C=C of Ar), 1503 (CH=CH), 929 (C-F) |
| 16 | $\mathrm{B}_{16}$ | 1650 ( C=O), 1586 ( $\mathrm{C}=\mathrm{C}$ of Ar), 1505 ( $\mathrm{CH}=\mathrm{CH}), 1178$ (-N(CH3)2 ), 921 (C-F) |
| 17 | $\mathrm{B}_{17}$ | 3450 (O-H), 1648 ( C=O), 1606 (C=C of Ar), 1510 ( $\mathrm{CH}=\mathrm{CH}), 1225$ (-OCH3), 925 (C-F) |
| 18 | $\mathrm{B}_{18}$ | 1653 ( C=O), 1605 (C=C of Ar), 1595 (C=N), 1508 (CH=CH), 1385 (C-N), 922 (C-F) |
| 19 | $\mathrm{B}_{19}$ | 1645 ( C=O), 1603 (C=C of Ar), 1590 (C=N), 1502 (CH=CH), 1370 (C-N), 923 (C-F) |
| 20 | $\mathrm{B}_{20}$ | 1650 ( C=O), 1605 (C=C of Ar), 1581 (C=N), 1505 (CH=CH), 1373 (C-N), 929 (C-F) |
| 21 | $\mathrm{B}_{21}$ | 1652 ( C=O), 1605 (C=C of Ar), 1588 (C=N), 1506 (CH=CH), 1375 (C-N), 921 (C-F) |
| 22 | $\mathrm{B}_{22}$ | 1655 ( C=O), 1610 (C=C of Ar), 1505 (CH=CH), 624 (C-S), 923 (C-F) |
| 23 | $\mathrm{B}_{23}$ | 1658 ( C=O), 1605 (C=C of Ar), 1503 (CH=CH), 923 (C-F) |
| 24 | $\mathrm{B}_{24}$ | 3460 (O-H), 1648 (C=O), 1606 (C=C of Ar), 1505 (CH=CH), 924 (C-F) |
| 25 | $\mathrm{B}_{25}$ | 1650 ( C=O), 1605 (C=C of Ar), 1502 (CH=CH), 929 (C-F) |

Table No.3: ${ }^{1} \mathrm{H}$ NMR spectral data of chalcones

| S.No | Compound | Chemical shift ( $\delta$ ) in ppm |
| :---: | :---: | :---: |
| 1 | $\mathrm{B}_{1}$ | $\begin{gathered} 2.40\left(3 \mathrm{H}, \mathrm{~s}, \mathrm{Ar}^{\left.-\mathrm{CH}_{3}\right), 7.23(1 \mathrm{H}, \mathrm{~d}, J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.73(1 \mathrm{H}, \mathrm{~d}, J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}),} \begin{array}{c} 7.20-7.78(7 \mathrm{H}, \mathrm{Ar}-\mathrm{H}) \end{array}\right. \\ \hline \end{gathered}$ |
| 2 | $\mathrm{B}_{2}$ | 7.15 (1H, d, $J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.62$ (1H, d, $J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}), 7.05-7.71$ (7H, Ar-H) |
| 3 | $\mathrm{B}_{3}$ | 7.45 (1H, d, $J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.82(1 \mathrm{H}, \mathrm{d}, J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}), 7.38-8.20$ (7H, Ar-H) |
| 4 | $\mathrm{B}_{4}$ | 7.43 (1H, d, $J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.80$ (1H, d, $J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}), 7.36-8.21$ (7H, Ar-H) |
| 5 | $\mathrm{B}_{5}$ | 7.40 (1H, d, $J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.73$ (1H, d, $J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}), 7.15-8.10$ (6H, Ar-H) |
| 6 | $\mathrm{B}_{6}$ | 7.68 (1H, d, $J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.85$ ( $1 \mathrm{H}, \mathrm{d}, J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}), 7.42-8.20$ (6H, Ar-H) |
| 7 | $\mathrm{B}_{7}$ | 7.49 (1H, d, $J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.65$ (1H, d, $J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}), 7.12-8.60$ (6H, Ar-H) |
| 8 | B8 | 7.40 (1H, d, $J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.62$ ( $1 \mathrm{H}, \mathrm{d}, J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}), 7.20-8.55$ (7H, Ar-H) |
| 9 | B9 | 7.43 (1H, d, $J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.68$ (1H, d, $J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}), 7.21-8.59$ (7H, Ar-H) |
| 10 | $\mathrm{B}_{10}$ | $\begin{gathered} 7.38(1 \mathrm{H}, \mathrm{~d}, J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), \\ \\ 7.52(1 \mathrm{H}, \mathrm{~d}, J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}), 6.89(1 \mathrm{H}, \mathrm{~s}, \mathrm{Ar}-\mathrm{OH}), \\ \hline \end{gathered}$ |
| 11 | $\mathrm{B}_{11}$ | $\begin{gathered} 2.50\left(3 \mathrm{H} . \mathrm{s}, \mathrm{Ar}_{\mathrm{CH}}^{3}\right), 7.40(1 \mathrm{H}, \mathrm{~d}, J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.65(1 \mathrm{H}, \mathrm{~d}, J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}), \\ 7.15-8.53(6 \mathrm{H}, \mathrm{Ar}-\mathrm{H}) \end{gathered}$ |
| 12 | $\mathrm{B}_{12}$ | $\begin{gathered} 7.15(1 \mathrm{H}, \mathrm{~d}, J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.64(1 \mathrm{H}, \mathrm{~d}, J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}), 7.12-7.58(5 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), \\ 3.78\left(3 \mathrm{H}, \mathrm{~s}, \mathrm{Ar}-\mathrm{OCH}_{3}\right), 3.88\left(6 \mathrm{H}, \mathrm{~s}, 2 \mathrm{x} \mathrm{Ar}-\mathrm{OCH}_{3}\right) \end{gathered}$ |
| 13 | $\mathrm{B}_{13}$ | $\begin{gathered} 6.10\left(2 \mathrm{H}, \mathrm{~s},-\mathrm{O}-\mathrm{CH}_{2} \mathrm{O}-\right), 6.88(1 \mathrm{H}, \mathrm{~d}, J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.69(1 \mathrm{H}, \mathrm{~d}, J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}), \\ 7.10-7.29(6 \mathrm{H}, \mathrm{Ar}-\mathrm{H}) \end{gathered}$ |
| 14 | $\mathrm{B}_{14}$ | $\begin{gathered} 2.45\left(3 \mathrm{H}, \mathrm{~s}, \mathrm{Ar}^{\left.-\mathrm{CH}_{3}\right), 6.85(1 \mathrm{H}, \mathrm{~d}, J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.65(1 \mathrm{H}, \mathrm{~d}, J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}),} \begin{array}{c} 6.58-7.90(8 \mathrm{H}, \mathrm{Ar}-\mathrm{H}) \end{array}\right. \\ \hline \end{gathered}$ |
| 15 | $\mathrm{B}_{15}$ | 7.23 (1H, d, $J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.71$ (1H, d, $J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar})$, 7.18-7.95 (5H, Ar-H) |
| 16 | $\mathrm{B}_{16}$ | $\begin{gathered} 3.10\left(6 \mathrm{H}, \mathrm{~s},-\mathrm{N}\left(\mathrm{CH}_{3}\right)_{2}, 6.88(1 \mathrm{H}, \mathrm{~d}, J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.75(1 \mathrm{H}, \mathrm{~d}, J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}),\right. \\ 6.65-7.90(7 \mathrm{H}, \mathrm{Ar}-\mathrm{H}) \end{gathered}$ |
| 17 | $\mathrm{B}_{17}$ | $\begin{gathered} 7.21(1 \mathrm{H}, \mathrm{~d}, J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.68(1 \mathrm{H}, \mathrm{~d}, J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}), 7.20-7.93(6 \mathrm{H}, \mathrm{Ar}-\mathrm{H}), \\ 6.75(1 \mathrm{H.s}, \mathrm{Ar}-\mathrm{OH}), 3.82\left(3 \mathrm{H}, \mathrm{~s}, \mathrm{Ar}^{2}-\mathrm{OCH}_{3}\right) \end{gathered}$ |
| 18 | $\mathrm{B}_{18}$ | 7.15 (1H, d, $J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.65$ ( $1 \mathrm{H}, \mathrm{d}, J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}$ ), 6.30-8.15 (7H, Ar-H) |
| 19 | $\mathrm{B}_{19}$ | 7.18 (1H, d, $J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.70$ (1H, d, $J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}), 7.12-8.20$ (7H, Ar-H) |
| 20 | $\mathrm{B}_{20}$ | 7.15 (1H, d, $J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.75$ (1H, d, $J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}), 7.20-8.15$ (7H, Ar-H) |
| 21 | $\mathrm{B}_{21}$ | 7.10 (1H, d, $J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.70$ ( $1 \mathrm{H}, \mathrm{d}, J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar})$, 6.35-7.90 (7H, Ar-H) |
| 22 | $\mathrm{B}_{22}$ | 7.12 (1H, d, $J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.70$ (1H, d, $J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}), 6.62-8.10$ (6H, Ar-H) |
| 23 | $\mathrm{B}_{23}$ | 7.35 (1H, d, $J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.60$ ( $1 \mathrm{H}, \mathrm{d}, J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}), 7.20-8.90$ ( $12 \mathrm{H}, \mathrm{Ar}-\mathrm{H}$ ) |
| 24 | $\mathrm{B}_{24}$ | $\begin{gathered} 7.28(1 \mathrm{H}, \mathrm{~d}, J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.59(1 \mathrm{H}, \mathrm{~d}, J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}), 6.85(1 \mathrm{H}, \mathrm{~s}, \mathrm{Ar}-\mathrm{OH}), \\ \\ \\ 7.21-7.89(7 \mathrm{H}, \mathrm{Ar}-\mathrm{H}) \end{gathered}$ |
| 25 | B25 | 7.21 (1H, d, $J=17 \mathrm{~Hz},-\mathrm{CO}-\mathrm{CH}=), 7.62$ (1H, d, $J=17 \mathrm{~Hz},=\mathrm{CH}-\mathrm{Ar}), 7.11-7.90$ (8H, Ar-H) |

Vudumula Kotireddy and Venkata Ramana K. / Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry. 5(1), 2017, 1-12.
Table No.4: Experimental and predicted MIC ( $\mu \mathrm{g} / \mathrm{mL}$ ) values of training set and test set molecules based on atom based 3D-QSAR model (Antibacterial activity)

| S.No | Compound code | B.subtilis <br> MIC $(\boldsymbol{\mu g} / \mathbf{m L}$ ) | Experimental <br> -log(MIC) | Predicted-log (MIC) <br> (Training set) | Predicted-log (MIC) <br> (Test set) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | $\mathrm{~B}_{1}$ | 128 | -2.10721 | -1.99786 | --- |
| 2 | $\mathrm{~B}_{2}$ | 64 | -1.80618 | --- | -1.8522 |
| 3 | $\mathrm{~B}_{3}$ | 64 | -1.80618 | -1.78244 | --- |
| 4 | $\mathrm{~B}_{4}$ | 64 | -1.80618 | -1.83539 | --- |
| 5 | $\mathrm{~B}_{5}$ | 32 | -1.50515 | -1.77385 | --- |
| 6 | $\mathrm{~B}_{6}$ | 64 | -1.80618 | --- | -1.61438 |
| 7 | $\mathrm{~B}_{7}$ | 32 | -1.50515 | -1.4236 | --- |
| 8 | $\mathrm{~B}_{8}$ | 128 | -2.10721 | -2.13336 | --- |
| 9 | $\mathrm{~B}_{9}$ | 128 | -2.10721 | -2.08065 | --- |
| 10 | $\mathrm{~B}_{10}$ | 256 | -2.40824 | -2.43568 | --- |
| 11 | $\mathrm{~B}_{11}$ | 128 | -2.10721 | --- | -2.11693 |
| 12 | $\mathrm{~B}_{12}$ | 64 | -1.80618 | -1.84143 | --- |
| 13 | $\mathrm{~B}_{13}$ | 256 | -2.40824 | --- | -2.24238 |
| 14 | $\mathrm{~B}_{14}$ | 128 | -2.10721 | -2.20928 | --- |
| 15 | $\mathrm{~B}_{15}$ | 64 | -1.80618 | -1.87677 | --- |
| 16 | $\mathrm{~B}_{16}$ | 64 | -1.80618 | -1.79833 | --- |
| 17 | $\mathrm{~B}_{17}$ | 128 | -2.10721 | -2.18291 | --- |
| 18 | $\mathrm{~B}_{18}$ | 128 | -2.10721 | -2.16989 | --- |
| 19 | $\mathrm{~B}_{19}$ | 128 | -2.10721 | -2.19334 | --- |
| 20 | $\mathrm{~B}_{20}$ | 128 | -2.10721 | -2.123 | --- |
| 21 | $\mathrm{~B}_{21}$ | 256 | -2.40824 | -2.33018 | --- |
| 22 | $\mathrm{~B}_{22}$ | 128 | -2.10721 | -2.0912 | --- |
| 23 | $\mathrm{~B}_{23}$ | 256 | -2.40824 | -2.34953 | --- |
| 24 | $\mathrm{~B}_{24}$ | 264 | -2.4216 | --- | -2.05839 |
| 25 | $\mathrm{~B}_{25}$ | 256 | -2.40824 | -2.01035 | --- |

Table No.5: Antibacterial activity of chalcones (compounds B $\mathbf{B}_{1}$ to $B_{12}$ ): (Expressed as MIC in $\mu \mathrm{g} / \mathrm{mL}$ )

| S.No | z | R | B.subtilis | S.aureus | E.coli | P.vulgaris |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | $\mathrm{B}_{1}$ | 4"-methyl phenyl | 128 | 128 | 64 | 64 |
| 2 | $\mathrm{B}_{2}$ | 4"-fluorophenyl | 64 | 128 | 64 | 128 |
| 3 | $\mathrm{B}_{3}$ | 4"-chlorophenyl | 64 | 128 | 128 | 64 |
| 4 | $\mathrm{B}_{4}$ | 2"-chlorophenyl | 64 | 128 | 128 | 64 |
| 5 | B5 | 2",4"-difluorophenyl | 33 | 64 | 33 | 33 |
| 6 | $\mathrm{B}_{6}$ | 2",4-dichlorophenyl | 64 | 64 | 32 | 128 |
| 7 | $\mathrm{B}_{7}$ | 2"-chloro-5"-nitro phenyl | 33 | 128 | 128 | 128 |
| 8 | B8 | 3"-nitro phenyl | 128 | 256 | 128 | 256 |
| 9 | B9 | 4"-nitro phenyl | 128 | 256 | 128 | 128 |
| 10 | $\mathrm{B}_{10}$ | 3"-hydroxyphenyl | 256 | 256 | 128 | 256 |
| 11 | $\mathrm{B}_{11}$ | 3"-nitro-4"-methyl phenyl | 128 | 64 | 128 | 128 |
| 12 | $\mathrm{B}_{12}$ | 3",4",5"-trimethoxyphenyl | 64 | 64 | 64 | 32 |
| 13 | $\mathrm{B}_{13}$ | 3",4"-methylendioxyphenyl | 256 | 128 | 256 | 128 |
| 14 | $\mathrm{B}_{14}$ | 1"-phenyl-3"methylpyrazole-4"-yl | 128 | 128 | 128 | 256 |
| 15 | $\mathrm{B}_{15}$ | 5"-bromofuran-2"-yl | 64 | 64 | 32 | 128 |
| 16 | $\mathrm{B}_{16}$ | 4"-dimethylaminophenyl | 64 | 128 | 64 | 64 |
| 17 | $\mathrm{B}_{17}$ | 3"-methoxy-4"-hydroxyphenyl | 128 | 128 | 128 | 128 |
| 18 | $\mathrm{B}_{18}$ | 2"-pyridinyl | 128 | 256 | 128 | 256 |
| 19 | $\mathrm{B}_{19}$ | 3"-pyridinyl | 128 | 256 | 256 | 256 |
| 20 | $\mathrm{B}_{20}$ | 4"-pyridinyl | 128 | 128 | 128 | 128 |
| 21 | $\mathrm{B}_{21}$ | 2"-pyrrolyl | 256 | 256 | 64 | 64 |
| 22 | $\mathrm{B}_{22}$ | 2"-thienyl | 128 | 64 | 128 | 128 |
| 23 | $\mathrm{B}_{23}$ | 9"-anthracenyl | 256 | 128 | 128 | 256 |
| 24 | $\mathrm{B}_{24}$ | 4"-hydroxyphenyl | 264 | 128 | 64 | 64 |
| 25 | $\mathrm{B}_{25}$ | Phenyl | 256 | 256 | 256 | 256 |
| 26 | Standard (Ampicillin) | --- | < 1 | < 1 | < 1 | < 1 |

Table No.5: Summary of atom based 3D QSAR results

| S.No | PLS Factors | SD | $\mathbf{R}^{\mathbf{2}}$ | $\mathbf{F}$ | $\mathbf{P}$ | RMSE | Q-squared | Pearson-R |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | 4 | 0.1406 | 0.7922 | 14.3 | $5.28 \mathrm{e}-05$ | 0.2 | 0.4647 | 0.8391 |

Available online: www.uptodateresearchpublication.com January - March

Vudumula Kotireddy and Venkata Ramana K. / Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry. 5(1), 2017, 1-12.
Table No.6: Experimental and predicted MIC ( $\mu \mathrm{g} / \mathrm{mL}$ ) values of training set and test set molecules based on atom based 3D-QSAR model (Antibacterial activity)

| S.No | Compound code | S.aureus <br> MIC( $\mathbf{\mu g} / \mathbf{m L}$ ) | Experimental <br> $-\mathbf{l o g}(\mathbf{M I C )}$ | Predicted-log(MIC) <br> (Training set) | Predicted-log(MIC) <br> (Test set) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | $\mathrm{~B}_{1}$ | 128 | -2.10721 | -2.03134 | --- |
| 2 | $\mathrm{~B}_{2}$ | 128 | -2.10721 | -2.02153 | --- |
| 3 | $\mathrm{~B}_{3}$ | 128 | -2.10721 | -2.03373 | --- |
| 4 | $\mathrm{~B}_{4}$ | 128 | -2.10721 | -2.03405 | --- |
| 5 | $\mathrm{~B}_{5}$ | 64 | -1.80618 | -1.97364 | --- |
| 6 | $\mathrm{~B}_{6}$ | 64 | -1.80618 | --- | -1.94537 |
| 7 | $\mathrm{~B}_{7}$ | 128 | -2.10721 | --- | -2.10334 |
| 8 | $\mathrm{~B}_{8}$ | 256 | -2.40824 | -2.49357 | --- |
| 9 | $\mathrm{~B}_{9}$ | 256 | -2.40824 | -2.38831 | --- |
| 10 | $\mathrm{~B}_{10}$ | 256 | -2.40824 | --- | -2.25866 |
| 11 | $\mathrm{~B}_{11}$ | 64 | -1.80618 | -1.85607 | --- |
| 12 | $\mathrm{~B}_{12}$ | 64 | -1.80618 | -1.80874 | --- |
| 13 | $\mathrm{~B}_{13}$ | 128 | -2.10721 | -2.12386 | --- |
| 14 | $\mathrm{~B}_{14}$ | 128 | -2.10721 | -2.09377 | --- |
| 15 | $\mathrm{~B}_{15}$ | 64 | -1.80618 | -1.92587 | --- |
| 16 | $\mathrm{~B}_{16}$ | 128 | -2.10721 | -2.06055 | --- |
| 17 | $\mathrm{~B}_{17}$ | 128 | -2.10721 | --- | -2.03624 |
| 18 | $\mathrm{~B}_{18}$ | 256 | -2.40824 | -2.39162 | --- |
| 19 | $\mathrm{~B}_{19}$ | 256 | -2.40824 | -2.37156 | --- |
| 20 | $\mathrm{~B}_{20}$ | 128 | -2.10721 | -2.15377 | --- |
| 21 | $\mathrm{~B}_{21}$ | 256 | -2.40824 | -2.38607 | --- |
| 22 | $\mathrm{~B}_{22}$ | 64 | -1.80618 | -1.74819 | --- |
| 23 | $\mathrm{~B}_{23}$ | 128 | -2.10721 | -2.1409 | --- |
| 24 | $\mathrm{~B}_{24}$ | -28 | --- |  |  |
| 25 | $\mathrm{~B}_{25}$ | 128 | -2.10721 | -2.10705 | -2.11896 |

Table No.7: Summary of atom based 3D QSAR results

| S.No | PLS Factors | SD | $\mathbf{R}^{\mathbf{2}}$ | F | P | RMSE | Q-squared | Pearson-R |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | 4 | 0.0765 | 0.9031 | 35 | $1.94 \mathrm{e}-07$ | 0.16 | 0.4858 | 0.8799 |

## General scheme of reaction



4-chloroacetophenone Aromatic/ Chalcone derivative Heterocyclic aldehyde
Available online: www.uptodateresearchpublication.com January - March

Vudumula Kotireddy and Venkata Ramana K. / Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry. 5(1), 2017, 1-12.


Figure No.1: Atom based 3D-QSAR Model of chalcones along with alignment of structures (Blue cubes indicate favorable regions while red cubes indicate unfavorable region for the activity) against B.subtilis


Figure No.2: Atom based 3D QSAR model visualized in the context of highest active compound $B_{7}$ against B.subtilis


Figure No.3: Atom based 3D QSAR model visualized in the context of lowest active compound $B_{25}$ against B.subtilis


Figure No.4: Atom based 3D-QSAR Model of chalcones along with alignment of structures (Blue cubes indicate favorable regions while red cubes indicate unfavorable region for the activity) against S.aureus


Figure No.5: Atom based 3D QSAR model visualized in the context of highest active compound B $_{6}$ against S.aureus


Figure No.6: Atom based 3D QSAR model visualized in the context of lowest active compound $B_{25}$ against S.aureus

## CONCLUSION

The above results clearly indicated the importance of electron withdrawing groups in increasing the antibacterial activity. When two or more such substituents present on the benzene ring, cumulative effect was observed as seen in the case of $\mathrm{B}_{5}$ and $\mathrm{B}_{6}$ having difluoro and dichloro substitution respectively. However, compounds with electron releasing substituents as seen in the case of $\mathrm{B}_{12}$ and $\mathrm{B}_{16}$ also enhanced the activity. Substitution of electron releasing or electron with drawing groups on the aromatic or heteroaromatic ring at varies positions can be synthesized to concluded with respect to the influence of electronic effects on the antimicrobial activity.

## ACKNOWLEDGEMENT

The authors wish to express their sincere gratitude to Department of Pharmaceutical Chemistry, A. S. N Pharmacy College, Burripalem Road, Tenali, Andhra Pradesh, India for providing necessary facilities to carry out this research work.

Available online: www.uptodateresearchpublication.com

## CONFLICT OF INTEREST

We declare that we have no conflict of interest.

## BIBLIOGRAPHY

1. Anshu D, Ruby S, Dharmendra S, Ashok L Asha S. et al. Regioselective Synthesis of Diltiazem Analogue Pyrazolo [4, 3-c] [1, 5] benzothiazepines and Antifungus Activity, Phosphorus, Sulfur, Silicon Relat, Elem, 185(11), 2010, 2472-2479.
2. Ghotekar D S, Joshi R S, Mandhane P G, Bhagat S S, Gill C H. Synthesis of some biologically important fluorinated 3chlorochromones and 1, 5-benzothiazepines as antimicrobial and antifungal agents, Indian J. Chem., Sect, B, 49B(9), 2010, 1267.
3. Pant S, Sharma P, Pant U C. Syntheses of 1, 5-Benzothiazepines: Part XXXVI-Syntheses and Antiminium Inhibitory Concentration robial Evaluation of 2-(2-Chlorophenyl)-4-(4-chlorophenyl/2-thienyl)-2, 5-dihydro-8-

January - March
substituted-1, 5-benzothiazepines, Phosphorus, Sulfur, Silicon Relat. Elem, 183(9), 2008, 2974-2983.
4. Desai K G, Desai K R. Minium Inhibitory Concentration rowave enhanced hetrerocyclization: a conveinient procedure for anitminium Inhibitory Concentrationrobial 1, 5 benzothiazepines, Indian J. Chem., Sect, B, 46B(1-6), 2007, 1179-1186.
5. Garg N, Chandra T, Archana Jain A B, Kumar A. Synthesis and evaluation of some new substituted benzothiazepine and benzoxazepine derivatives as anticonvulsant agents, Eur. J. Med. Chem, 45(4), 2010, 1529-1535.
6. Sarro G D, Chimirri A, Sarro A D, Gitto R, Grasso S, Zappala M. 5H-[1, 2, 4] Oxadiazolo [5, 4-d] [1, 5] benzothiazepines as anticonvulsant agents in DBA/2 minium Inhibitory Concentratione, Eur. J. Med Chem, 30(12), 1995, 925-929.
7. Saini R K, Joshi Y C, Joshi P. Phosphorus, Sulfur, Silicon Relat. Elem, 183(9), 2008, 2181.
8. Grandolini G, Perioli L, Ambrogi V. Syntheses of 1, 5-Benzothiazepines: Part XXXVI-Syntheses and antiminium Inhibitory Concentrationrobial Evaluation of 2-(2-Chlorophenyl) -4- (4-chlorophenyl/ 2thienyl) -2, 5-dihydro-8-substituted-1, 5benzothiazepines, Eur. J. Med. Chem, 34(9), 1999, 701-709.
9. Yamada S, Mori Y, Morimatsu K, Ishizu Y, Ozaki Y, Yoshioka R, Nakatani T, Seko H. Asymmetric Reduction of a 1, 5Benzothiazepine Derivative with Sodium Borohydride- (S) - $\alpha$-Amino Acids: An Efficient Synthesis of a Key Intermediate of Diltiazem, J. Org. Chem, 61(16), 1996, 8586-8590.
10. Maayan S, Ohad N and Soliman K. Chalcones as potent tyrosinase inhibitors: the importance of a 2, 4-substituted resorcinol moiety, Bioorg. Med. Chem, 13(2), 2005, 433-441.
11. Nowakowska. A review of anti-infective and anti-inflammatory chalcones, Eur. J. Med. Chem, 4(2), 2007, 125-137.
12. Go M L, Wu X and Liu X L. Chalcones: An Update on Cytotoxic and Chemo protective Properties, Current Medicinal Chemistry, 12(4), 2005, 483-499.
13. Mark C and Nagarathnam D. Cytotoxicities of some flavonoid analogues, J. Nat. Prod, 54(6), 1991, 1656-1660.

Please cite this article in press as: Vudumula Kotireddy and Venkata Ramana K. Synthesis, screening and QSAR analysis of chalcone derivatives as potential anti-bacterial agents, Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry, 5(1), 2017, 1-12.

